CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-30 | Tyree James L Director | Sale | −3,460 | $2.46 | $9K | 45,791 |
| 2024-12-18 | Smalling Ralph Head of Regulatory | Grant or award | +15,525 | 31,847 | ||
| 2024-12-18 | Smalling Ralph Head of Regulatory | Grant or award · Stock Option (right to buy) | +21,100 | 21,100 | ||
| 2024-12-18 | Ryder Sean General Counsel | Grant or award | +22,000 | 41,388 | ||
| 2024-12-18 | Ryder Sean General Counsel | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2024-12-18 | Yu Yong VP, Clinical Trial Operations | Grant or award | +29,000 | 39,869 | ||
| 2024-12-18 | Yu Yong VP, Clinical Trial Operations | Grant or award · Stock Option (right to buy) | +39,000 | 39,000 | ||
| 2024-12-18 | Cappello Joseph VP, Pharmaceutical Development | Grant or award | +29,000 | 43,653 | ||
| 2024-12-18 | Cappello Joseph VP, Pharmaceutical Development | Grant or award · Stock Option (right to buy) | +39,000 | 39,000 | ||
| 2024-12-18 | Zak Lourie S. Chief Financial Officer | Grant or award | +41,650 | 82,452 | ||
| 2024-12-18 | Zak Lourie S. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +56,525 | 56,525 | ||
| 2024-12-18 | Zindrick Thomas President and CEO | Grant or award | +134,500 | 171,872 | ||
| 2024-12-18 | Zindrick Thomas President and CEO | Grant or award · Stock Option (right to buy) | +183,000 | 183,000 | ||
| 2024-12-16 | Zindrick Thomas President and CEO | Sale | −14,315 | $2.34 | $33K | 37,372 |
| 2024-12-16 | Zak Lourie S. Chief Financial Officer | Sale | −2,103 | $2.34 | $5K | 40,802 |
| 2024-12-16 | Smalling Ralph Head of Regulatory | Sale | −2,510 | $2.34 | $6K | 16,322 |
| 2024-12-16 | Cappello Joseph VP, Pharmaceutical Development | Sale | −6,300 | $2.34 | $15K | 14,653 |
| 2024-10-18 | Scigalla Paul Chief Medical Officer | Grant or award · Stock Option (right to buy) | +16,666 | 16,666 | ||
| 2024-10-18 | Scigalla Paul Chief Medical Officer | Grant or award · Stock Option (right to buy) | +16,666 | 16,666 | ||
| 2024-09-13 | Szalay Aladar 10% owner | Sale | −33,080 | $2.57 | $85K | 599,821 |
Page 6 of 9 · 170 trades